DG
HCAT icon

Daventry Group’s Health Catalyst HCAT Stock Holding History

Daventry Group’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,509,480
Closed -$17.7M – 9
2024
Q4 		$17.7M Buy
2,509,480
+91,878
+4% +$732K 6.78% 8
2024
Q3 		$19.7M Buy
2,417,602
+170,549
+8% +$1.23M 7.83% 8
2024
Q2 		$14.4M Buy
2,247,053
+84,178
+4% +$540K 6.41% 8
2024
Q1 		$16.3M Buy
2,162,875
+242,500
+13% +$2.21M 6.51% 7
2023
Q4 		$17.8M Buy
1,920,375
+346,200
+22% +$2.83M 7.64% 8
2023
Q3 		$15.9M Sell
1,574,175
-62,936
-4% -$751K 10.16% 5
2023
Q2 		$20.5M Hold
1,637,111
– – 15.15% 3
2023
Q1 		$19.1M Buy
1,637,111
+197,497
+14% +$2.52M 13.37% 6
2022
Q4 		$15.3M Buy
1,439,614
+587,110
+69% +$5.67M 13.21% 5
2022
Q3 		$8.27M Hold
852,504
– – 11.18% 6
2022
Q2 		$12.4M Buy
852,504
+291,743
+52% +$4.97M 16.84% 2
2022
Q1 		$14.7M Buy
560,761
+250,353
+81% +$7.1M 15.24% 3
2021
Q4 		$12.3M Buy
+310,408
New +$14.1M 13.84% 3

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $380M AUM 20.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Daventry Group's HCAT Position: Q1 2025 in Review

Daventry Group sold out of Health Catalyst (HCAT) in Q1 2025, closing a stake of 2,509,480 shares — an estimated $17.7M sold.

Daventry Group first reported a position in HCAT in Q4 2021 and held it in 13 quarters. The position peaked at $20.5M in Q2 2023. 165 funds tracked by Wall St. Rank hold HCAT as of Q1 2025.

  • Daventry Group reported no remaining Health Catalyst position as of Q1 2025 after selling out during the quarter.
  • Daventry Group sold 2,509,480 Health Catalyst shares in Q1 2025, an estimated $17.7M.
  • Daventry Group first reported a position in Health Catalyst in Q4 2021 and held it in 13 quarters.
  • Daventry Group's Health Catalyst position peaked at $20.5M in Q2 2023.
  • 165 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2025.

Based on Daventry Group's 13F filing for Q1 2025, filed 15 May 2025.